Akebia Therapeutics, Inc. (AKBA) Income Statement

The 2025 growth surge (75.8% then 43.1% then 57.0% year-over-year) looks less like a durable franchise inflection and more like episodic product demand, given the immediate reversal to -6.6% and -21.4% in the two most recent quarters. Investors should monitor whether 2026 stabilization depends on a repeat cycle or a structural demand driver, since the $13.4M sequential decline from 2025Q2 to 2026Q2 is too steep to be explained by seasonality alone.

A 35-point swing in gross margin across a single year suggests COGS behaves more like a variable royalty or licensing-linked line than a fixed manufacturing base, making profitability sensitive to revenue composition rather than volume efficiency. The current 78.8% level remains well below the 91.7% peak and sits at Halozyme's 78.1% gross margin but far below its 58.4% operating margin, implying Akebia has not converted gross margin into comparable downstream pricing power.

SG&A has been remarkably sticky at $25.7M-$30.4M across the eight quarters where it is reported, so incremental revenue has flowed inconsistently to operating income — 2025Q1-Q2 delivered 23%+ operating margins while 2026Q2 sits at -12.9% on only about 14% lower revenue. This asymmetry suggests the cost base is largely fixed and that revenue declines bite disproportionately to gains, though SG&A is unreported for 2024Q1-Q2 and the two-year trend there remains data unavailable.

The 2025Q1-Q3 run of positive operating income appears to have been driven by a favorable combination of elevated revenue ($57-63M) and suppressed R&D ($9.8-14.6M per quarter), not by structural cost reduction, since SG&A continued rising through the same period. The 2025Q4 R&D jump to $26.6M alone erased the operating profit, implying the path to sustained profitability hinges on whether Akebia can hold R&D below roughly $15M without impairing the revenue line — a tension the reported figures suggest has not yet been resolved.